P

reventing migraines is shaping up to be the drug industry’s next big gold rush, a multibillion-dollar opportunity with four contenders vying to claim its lion’s share. But just which company triumphs will depend on satisfying patients, winning over payers, and — maybe — lining the pockets of doctors.

The key is a protein called CGRP, which plays a role in the dilation of the brain’s blood vessels. Block it and you can prevent the painful, debilitating headaches that plague roughly 40 million Americans, studies have shown. It’s by no means a cure, but doctors say shaving a few headache days off of a migraine sufferer’s monthly burden can make a world of difference.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • CGRP-inhibition is a simplistic approach. Read my book on migraine published by Nova Science Publishers, New York, 2009: Adaptive Mechanisms in Migraine. Breaking the Migraine Code, for a comprehensive and realistic grip on migraine.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.